ID

16672

Description

Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20); ODM derived from: https://clinicaltrials.gov/show/NCT00310232

Link

https://clinicaltrials.gov/show/NCT00310232

Keywords

Versions (1)
  1. 7/31/16 7/31/16 -
Uploaded on

July 31, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Non-Small-Cell Lung Carcinoma NCT00310232

English

Eligibility Non-Small-Cell Lung Carcinoma NCT00310232

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. histologically confirmed non-small cell lung cancer (squamous cell, large cell, adenocarcinoma, or some combination of these), with clinical or pathological stage iii or iv, or recurrent disease; and
Description

nsclc stage III or IV

Data type

boolean

Alias
UMLS CUI [1]
C0278506
UMLS CUI [2]
C0278987
UMLS CUI [3]
C0278517
2. hemoglobin level at or below 120 g/l; and
Description

hemoglobin

Data type

boolean

Alias
UMLS CUI [1]
C0518015
3. at least 18 years of age;
Description

age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. systemic platinum-based chemotherapy for lung cancer during the previous two months or planned platinum-based chemotherapy within the next three months;
Description

systemic platinum-based chemotherapy

Data type

boolean

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C2266918
2. patients previously treated with high dose thoracic radiation (>10 fractions), or surgery, without objective evidence of disease recurrence;
Description

previous RTx or surgery, no evidenc of disease recurrence

Data type

boolean

Alias
UMLS CUI [1]
C0279134
UMLS CUI [2]
C0744961
UMLS CUI [3]
C0277556
3. planned high dose thoracic radiation therapy (>10 fractions);
Description

planned high dose thoracic radiation therapy

Data type

boolean

Alias
UMLS CUI [1]
C1514710
4. a clinically active malignancy, other than the underlying lung cancer which is expected to influence qol;
Description

clinically active malignancy

Data type

boolean

Alias
UMLS CUI [1]
C0006826
5. expected survival of three months or less;
Description

life expectancy

Data type

boolean

Alias
UMLS CUI [1]
C0023671
6. ecog performance status of 3 or 4 (see appendix d);
Description

ecog performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
7. multiple cns metastasis or a single cns lesion that does not demonstrate radiographic stability (screening ct of head required only if symptomatic, no radiographic follow-up of single resected lesions required);
Description

cns metastasis

Data type

boolean

Alias
UMLS CUI [1]
C0686377
8. blood transfusions within the last 14 days;
Description

blood transfusions

Data type

boolean

Alias
UMLS CUI [1]
C0005841
9. previous use of erythropoietin;
Description

previous use of erythropoietin

Data type

boolean

Alias
UMLS CUI [1]
C0199970
10. anemia due to factors other than cancer / radiotherapy (e.g. hemolysis or gastrointestinal bleeding);
Description

anemia

Data type

boolean

Alias
UMLS CUI [1]
C0002871
11. evidence of untreated folate or vitamin b12 deficiency;
Description

evidence of untreated folate or vitamin b12 deficiency

Data type

boolean

Alias
UMLS CUI [1]
C0042847
UMLS CUI [2]
C0016412
12. history of uncontrolled hypertension or diastolic blood pressure greater than 100 mm hg;
Description

uncontrolled hypertension or diastolic blood pressure

Data type

boolean

Alias
UMLS CUI [1]
C1868885
UMLS CUI [2]
C0235222
13. history of seizure disorder;
Description

seizure disorder

Data type

boolean

Alias
UMLS CUI [1]
C0014544
14. known hypersensitivity to mammalian cell-derived products, albumin or any component of the study drug;
Description

hypersensitivity to mammalian cell-derived products, albumin or any component of the study drug

Data type

boolean

Alias
UMLS CUI [1]
C0013182
15. pregnancy, lactation or parturition within the previous 30 days;
Description

pregnancy, lactation or parturition

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3]
C1148523
16. unwillingness or inability to complete the required qol questionnaires;
Description

compliance

Data type

boolean

Alias
UMLS CUI [1]
C1321605
17. mental incompetence, including psychiatric or addictive disorders which would preclude meaningful completion of questionnaires;
Description

condition precluding study compliance

Data type

boolean

Alias
UMLS CUI [1,1]
C1321605
UMLS CUI [1,2]
C0439801
UMLS CUI [1,3]
C0009488
18. geographically inaccessible for treatment or follow-up evaluations;
Description

geographically inaccessible for treatment or follow-up evaluations

Data type

boolean

Alias
UMLS CUI [1]
C0814423
19. currently enrolled in an ongoing therapeutic study;
Description

study participation status

Data type

boolean

Alias
UMLS CUI [1]
C2348568
Back to the top of the page

Similar models

Eligibility Non-Small-Cell Lung Carcinoma NCT00310232

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
nsclc stage III or IV
Item
1. histologically confirmed non-small cell lung cancer (squamous cell, large cell, adenocarcinoma, or some combination of these), with clinical or pathological stage iii or iv, or recurrent disease; and
boolean
C0278506 (UMLS CUI [1])
C0278987 (UMLS CUI [2])
C0278517 (UMLS CUI [3])
hemoglobin
Item
2. hemoglobin level at or below 120 g/l; and
boolean
C0518015 (UMLS CUI [1])
age
Item
3. at least 18 years of age;
boolean
C0001779 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
systemic platinum-based chemotherapy
Item
1. systemic platinum-based chemotherapy for lung cancer during the previous two months or planned platinum-based chemotherapy within the next three months;
boolean
C0392920 (UMLS CUI [1,1])
C2266918 (UMLS CUI [1,2])
previous RTx or surgery, no evidenc of disease recurrence
Item
2. patients previously treated with high dose thoracic radiation (>10 fractions), or surgery, without objective evidence of disease recurrence;
boolean
C0279134 (UMLS CUI [1])
C0744961 (UMLS CUI [2])
C0277556 (UMLS CUI [3])
planned high dose thoracic radiation therapy
Item
3. planned high dose thoracic radiation therapy (>10 fractions);
boolean
C1514710 (UMLS CUI [1])
clinically active malignancy
Item
4. a clinically active malignancy, other than the underlying lung cancer which is expected to influence qol;
boolean
C0006826 (UMLS CUI [1])
life expectancy
Item
5. expected survival of three months or less;
boolean
C0023671 (UMLS CUI [1])
ecog performance status
Item
6. ecog performance status of 3 or 4 (see appendix d);
boolean
C1520224 (UMLS CUI [1])
cns metastasis
Item
7. multiple cns metastasis or a single cns lesion that does not demonstrate radiographic stability (screening ct of head required only if symptomatic, no radiographic follow-up of single resected lesions required);
boolean
C0686377 (UMLS CUI [1])
blood transfusions
Item
8. blood transfusions within the last 14 days;
boolean
C0005841 (UMLS CUI [1])
previous use of erythropoietin
Item
9. previous use of erythropoietin;
boolean
C0199970 (UMLS CUI [1])
anemia
Item
10. anemia due to factors other than cancer / radiotherapy (e.g. hemolysis or gastrointestinal bleeding);
boolean
C0002871 (UMLS CUI [1])
evidence of untreated folate or vitamin b12 deficiency
Item
11. evidence of untreated folate or vitamin b12 deficiency;
boolean
C0042847 (UMLS CUI [1])
C0016412 (UMLS CUI [2])
uncontrolled hypertension or diastolic blood pressure
Item
12. history of uncontrolled hypertension or diastolic blood pressure greater than 100 mm hg;
boolean
C1868885 (UMLS CUI [1])
C0235222 (UMLS CUI [2])
seizure disorder
Item
13. history of seizure disorder;
boolean
C0014544 (UMLS CUI [1])
hypersensitivity to mammalian cell-derived products, albumin or any component of the study drug
Item
14. known hypersensitivity to mammalian cell-derived products, albumin or any component of the study drug;
boolean
C0013182 (UMLS CUI [1])
pregnancy, lactation or parturition
Item
15. pregnancy, lactation or parturition within the previous 30 days;
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C1148523 (UMLS CUI [3])
compliance
Item
16. unwillingness or inability to complete the required qol questionnaires;
boolean
C1321605 (UMLS CUI [1])
condition precluding study compliance
Item
17. mental incompetence, including psychiatric or addictive disorders which would preclude meaningful completion of questionnaires;
boolean
C1321605 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
geographically inaccessible for treatment or follow-up evaluations
Item
18. geographically inaccessible for treatment or follow-up evaluations;
boolean
C0814423 (UMLS CUI [1])
study participation status
Item
19. currently enrolled in an ongoing therapeutic study;
boolean
C2348568 (UMLS CUI [1])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial